Perspective Therapeutics (NYSEAMERICAN:CATX) Stock: Insider Robert Williamson III Purchases 25,000 Shares

Perspective Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Director Robert Williamson III bought 25,000 shares at an average price of $0.84, spending $21,000 and increasing his direct holdings by 87.8% to 53,473 shares.
  • Perspective Therapeutics shares were down 6.9%; the company also missed quarterly earnings and revenue expectations, reporting an EPS loss of $0.27 and revenue of $0.02 million.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $10.10, though some firms have lowered their targets or ratings.
  • MarketBeat previews the top five stocks to own by December 1st.

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX - Get Free Report) Director Robert Williamson III acquired 25,000 shares of the business's stock in a transaction that occurred on Tuesday, November 17th. The stock was bought at an average cost of $0.84 per share, for a total transaction of $21,000.00. Following the completion of the transaction, the director directly owned 53,473 shares in the company, valued at $44,917.32. This represents a 87.80% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Perspective Therapeutics Stock Down 6.9%

Shares of NYSEAMERICAN CATX opened at $0.86 on Wednesday. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. Perspective Therapeutics, Inc. has a 1-year low of $0.78 and a 1-year high of $6.16. The company has a fifty day moving average price of $2.02 and a 200 day moving average price of $3.42.

Perspective Therapeutics (NYSEAMERICAN:CATX - Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Perspective Therapeutics had a negative return on equity of 42.25% and a negative net margin of 55,866.82%. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, equities analysts expect that Perspective Therapeutics, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Perspective Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CATX. Dimensional Fund Advisors LP raised its stake in shares of Perspective Therapeutics by 391.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company's stock worth $1,877,000 after purchasing an additional 358,540 shares in the last quarter. Avidity Partners Management LP boosted its holdings in shares of Perspective Therapeutics by 88.4% in the 1st quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company's stock valued at $25,228,000 after buying an additional 2,839,266 shares during the last quarter. Seven Fleet Capital Management LP bought a new position in shares of Perspective Therapeutics in the first quarter valued at $1,581,000. Yu Fan bought a new position in shares of Perspective Therapeutics in the first quarter valued at $4,401,000. Finally, Commodore Capital LP bought a new position in shares of Perspective Therapeutics in the first quarter valued at $26,424,000. Institutional investors and hedge funds own 54.66% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the company. Wedbush reaffirmed an "outperform" rating and set a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research report on Tuesday, November 10th. BTIG Research reissued a "buy" rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. William Blair assumed coverage on Perspective Therapeutics in a research note on Friday, September 18th. They issued an "outperform" rating on the stock. BMO Capital Markets reaffirmed an "outperform" rating on shares of Perspective Therapeutics in a research report on Friday, October 30th. Finally, Royal Bank Of Canada cut shares of Perspective Therapeutics from an "outperform" rating to a "sector perform" rating and decreased their price target for the stock from $14.00 to $4.00 in a research note on Monday, October 26th. Nine research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $10.10.

Read Our Latest Research Report on CATX

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company's investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Further Reading

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Perspective Therapeutics Right Now?

Before you consider Perspective Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Perspective Therapeutics wasn't on the list.

While Perspective Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines